Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AIM Vaccine CoHKSE:06660 -1.47%61 WACC % is 10.74% as of Sep. 14, 2026, which is 16% above its 10-year median of 9.26. GuruFocus rates HKSE:06660 with a GF Score™ of 61/100 and a GF Value™ of HK$4.08 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 1,417 Biotechnology companies, AIM Vaccine Co ranks worse than 55.68% on this metric.
As of today (2026-09-14), AIM Vaccine Co's weighted average cost of capital is 10.74%%. AIM Vaccine Co's ROIC % is -2.90% (calculated using TTM income statement data).
AIM Vaccine Co earns returns that do not match up to its cost of capital. It will destroy value as it grows.
For a comprehensive WACC calculation, please access the WACC Calculator.
Because it costs money to raise capital. A firm that generates higher ROIC % than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.
As of today, AIM Vaccine Co's weighted average cost of capital is 10.74%%. AIM Vaccine Co's ROIC % is -2.90% (calculated using TTM income statement data).
AIM Vaccine Co earns returns that do not match up to its cost of capital. It will destroy value as it grows.
Be Aware
1. GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding latest one-year semi-annual average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together.
For companies that report quarterly, GuruFocus combines all of the most recent year's quarterly debt data from the beginning of the year to the year-end and calculates the average.
For companies that report semi-annually, GuruFocus combines all of the most recent year's semi-annual debt data from the start of the year to the year-end and calculates the average.
For companies that report annually, GuruFocus combines the beginning and ending annual debt data from the most recent year and then calculates the average.
2. The WACC formula discussed above does not include Preferred Stock. Please adjust if preferred stock is considered.
3. (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.
4. GuruFocus uses the latest TTM Interest Expense divided by the latest one-year semi-annual average debt to get the simplified cost of debt.
Related Terms
AIM Vaccine Co WACC % Historical Data
* Premium members only.
The historical data trend for AIM Vaccine Co's WACC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, AIM Vaccine Co's WACC %, along with its competitors' market caps and WACC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AIM Vaccine Co WACC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AIM Vaccine Co's WACC % distribution charts can be found below:
* The bar in red indicates where AIM Vaccine Co's WACC % falls into.
The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. The WACC is commonly referred to as the firm's cost of capital. Generally speaking, a company's assets are financed by debt and equity. WACC is the average of the costs of these sources of financing, each of which is weighted by its respective use in the given situation. By taking a weighted average, we can see how much interest the company has to pay for every dollar it finances.
WACC
=
E
/
(E + D)
*
Cost of Equity
+
D
/
(E + D)
*
Cost of Debt
*
(1 - Tax Rate)
1. Weights:
Generally speaking, a company's assets are financed by debt and equity. We need to calculate the weight of equity and the weight of debt.
The market value of equity (E) is also called "Market Cap". As of today, AIM Vaccine Co's market capitalization (E) is HK$2048.359 Mil.
The market value of debt is typically difficult to calculate, therefore, GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding the latest one-year semi-annual average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together. As of Jun. 2026, AIM Vaccine Co's latest one-year semi-annual average Book Value of Debt (D) is HK$1977.4563 Mil.
a) weight of equity = E / (E + D) = 2048.359 / (2048.359 + 1977.4563) = 0.5088
b) weight of debt = D / (E + D) = 1977.4563 / (2048.359 + 1977.4563) = 0.4912
2. Cost of Equity:
GuruFocus uses Capital Asset Pricing Model (CAPM) to calculate the required rate of return. The formula is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)
a) GuruFocus uses 10-Year Treasury Constant Maturity Rate as the risk-free rate. It is updated daily. The current risk-free rate is 4.969%. Please go to Economic Indicators page for more information. Please note that we use the 10-Year Treasury Constant Maturity Rate of the country/region where the company is headquartered. If the data for that country/region is not available, then we will use the 10-Year Treasury Constant Maturity Rate of the United States as default.
b) Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. AIM Vaccine Co's beta is 2.1449.
c) (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.
Cost of Equity = 4.969% + 2.1449 * 6% = 17.8384%
3. Cost of Debt:
GuruFocus uses latest TTM Interest Expense divided by the latest one-year semi-annual average debt to get the simplified cost of debt.
As of Jun. 2026, AIM Vaccine Co's interest expense (positive number) was HK$67.824 Mil. Its total Book Value of Debt (D) is HK$1977.4563 Mil.
Cost of Debt = 67.824 / 1977.4563 = 3.4299%.
4. Multiply by one minus TTM Tax Rate:
GuruFocus uses the most recent TTM Tax Expense divided by the most recent TTM Pre-Tax Income to calculate the tax rate. The calculated TTM tax rate is limited to between 0% and 100%. If the calculated tax rate is higher than 100%, it is set to 100%. If the calculated tax rate is less than 0%, it is set to 0%.
The latest calculated TTM Tax Rate = -10.689 / -832.206 = 1.28%.
AIM Vaccine Co's Weighted Average Cost Of Capital (WACC) for Today is calculated as:
WACC
=
E / (E + D)
*
Cost of Equity
+
D / (E + D)
*
Cost of Debt
*
(1 - Tax Rate)
=
0.5088
*
17.8384%
+
0.4912
*
3.4299%
*
(1 - 1.28%)
=
10.74%
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AIM Vaccine Co (HKSE:06660) has a WACC % of 10.74% as of Sep. 14, 2026. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on AIM Vaccine Co and its competitors. This is 16% above median its historical median of 9.26. Over the past decade, AIM Vaccine Co's WACC % has ranged from 8.68 to 11.03. According to the industry distribution chart, AIM Vaccine Co ranks #789 out of 1417 companies in the Biotechnology industry, placing it in the top 55.7%.
Is AIM Vaccine Co's WACC % too high?
AIM Vaccine Co's current WACC % of 10.74% is 16% above median its 10-year median of 9.26. Over the past 10 years, this metric has ranged from a low of 8.68 to a high of 11.03. The Biotechnology industry median WACC % is 10.21. AIM Vaccine Co's value of 10.74% is 5.2% above this industry median. Based on the distribution chart, AIM Vaccine Co ranks #789 out of 1417 companies in the Biotechnology industry, which is below the industry midpoint. Overall, AIM Vaccine Co has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does AIM Vaccine Co's WACC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, AIM Vaccine Co ranks #789 out of 1417 companies for WACC %. This places AIM Vaccine Co in the lower half of its industry. The industry median WACC % is 10.21. AIM Vaccine Co's value of 10.74% is 5.2% above this benchmark. Historically, AIM Vaccine Co's own WACC % has ranged from 8.68 to 11.03 over the past decade. While the company's 10-year median is 9.26 vs. the industry median of 10.21, AIM Vaccine Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good WACC % for a Biotechnology company?
The median WACC % among Biotechnology companies is 10.21, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a WACC % significantly above this median, while those in the bottom quartile fall well below. However, WACC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AIM Vaccine Co's current WACC % of 10.74% is 5.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high WACC % mean?
A high WACC % can signal that a stock is expensive relative to its fundamentals. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on AIM Vaccine Co and its competitors. For the Biotechnology industry, the median WACC % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AIM Vaccine Co's current WACC % is 10.74%, which is 16% above median its own 10-year median of 9.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AIM Vaccine Co stock overvalued right now?
Based on GuruFocus' analysis, AIM Vaccine Co (HKSE:06660) is currently considered Possible Value Trap. The stock's GF Value™ is HK$4.08, compared to a current price of HK$1.67 — trading 59.1% below its estimated fair value. The current WACC % is 10.74%, which is 16% above median its 10-year median of 9.26 and 5.2% above the Biotechnology industry median of 10.21. AIM Vaccine Co's overall GF Score™ is 61/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is WACC % calculated?
WACC % is calculated from a company's financial statements. For AIM Vaccine Co (HKSE:06660), the current WACC % is 10.74% as of Sep. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AIM Vaccine Co (HKSE:06660) Overvalued in 2026?
Based on GuruFocus' analysis, AIM Vaccine Co stock appears to be undervalued.
The current stock price of HK$1.67 is trading 59.1% below its estimated GF Value™ of HK$4.08.
GuruFocus considers AIM Vaccine Co to be Possible Value Trap.
Key valuation signals for HKSE:06660:
WACC %: 10.74% (16% above median its 10-year median of 9.26)
GF Value™: HK$4.08 vs. price of HK$1.67 (59.1% below fair value)
Industry Position: 5.2% above the Biotechnology median (#789 of 1417)
No single metric tells the full story. See the HKSE:06660 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AIM Vaccine Co Ltd is a China-based full-chain vaccine company engaged in the research and development, manufacturing, and commercialization of vaccine products. The company's commercialized products include recombinant HBV vaccines, freeze-dried human rabies vaccines, inactivated HAV vaccines, Group A, C, Y, and W135 meningococcal polysaccharide vaccines, bivalent inactivated HFRS vaccines, and mumps vaccines. The company generates the majority of its revenue from the PRC.
61GF Score
Get the complete analysis for HKSE:06660
WACC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06660 has been successfully added to your 
